Cargando…
Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial
OBJECTIVE: We investigated the association between obesity and biomarkers indicating cardiac or renal dysfunction or inflammation and their interaction with obesity and outcomes. METHODS: A total of 14 753 patients in the Apixaban for Reduction In STroke and Other ThromboemboLic Events in Atrial Fib...
Autores principales: | Sandhu, Roopinder K, Ezekowitz, Justin A, Hijazi, Ziad, Westerbergh, Johan, Aulin, Julia, Alexander, John H, Granger, Christopher B, Halvorsen, Sigrun, Hanna, Michael S, Lopes, Renato D, Siegbahn, Agneta, Wallentin, Lars |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6242013/ https://www.ncbi.nlm.nih.gov/pubmed/30487982 http://dx.doi.org/10.1136/openhrt-2018-000908 |
Ejemplares similares
-
Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas
por: Pol, Tymon, et al.
Publicado: (2021) -
Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
por: Christersson, Christina, et al.
Publicado: (2019) -
Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation
por: Rutherford, Ole-Christian Walter, et al.
Publicado: (2022) -
High prevalence of modifiable stroke risk factors identified in a pharmacy-based screening programme
por: Sandhu, Roopinder K, et al.
Publicado: (2016) -
Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation
por: Bahit, M Cecilia, et al.
Publicado: (2017)